tiprankstipranks
Advertisement
Advertisement

AU:PYC Stock Latest News

PYC Therapeutics Gains Safety Clearance to Escalate Dosing in PKD Trial
Company AnnouncementsPYC Therapeutics Gains Safety Clearance to Escalate Dosing in PKD Trial
21h ago
PYC Therapeutics Secures Shareholder Approval at Extraordinary General Meeting
PremiumCompany Announcements
PYC Therapeutics Secures Shareholder Approval at Extraordinary General Meeting
7d ago
PYC Therapeutics Wins Long-Term U.S. Patents for Lead RNA Drug Candidates
PremiumCompany Announcements
PYC Therapeutics Wins Long-Term U.S. Patents for Lead RNA Drug Candidates
15d ago
PYC Therapeutics Strengthens Financial Leadership with New CFO Appointment
PremiumCompany Announcements
PYC Therapeutics Strengthens Financial Leadership with New CFO Appointment
16d ago
PYC Therapeutics Announces Lapse of 700,000 Unlisted Options
PremiumCompany Announcements
PYC Therapeutics Announces Lapse of 700,000 Unlisted Options
1M ago
PYC’s VP-001 Eye Trial Reaches Phase 1 Finish Line, Setting Up the Next Investment Milestone
PremiumCompany AnnouncementsPYC’s VP-001 Eye Trial Reaches Phase 1 Finish Line, Setting Up the Next Investment Milestone
2M ago
PYC
PYC Therapeutics Nears an Inflection Point With Completion of Its VP-001 Retinal Trial
Premium
Company Announcements
PYC Therapeutics Nears an Inflection Point With Completion of Its VP-001 Retinal Trial
2M ago
PYC
PYC Therapeutics Resets CEO Pay to Sharpen Market Alignment and Performance Focus
Premium
Company Announcements
PYC Therapeutics Resets CEO Pay to Sharpen Market Alignment and Performance Focus
2M ago
PYC
PYC Therapeutics outlines limits of data and risk profile in investor update
PremiumCompany Announcements
PYC Therapeutics outlines limits of data and risk profile in investor update
2M ago
PYC
PYC Therapeutics Cuts Option Overhang as Multiple Incentive Securities Lapse
PremiumCompany Announcements
PYC Therapeutics Cuts Option Overhang as Multiple Incentive Securities Lapse
2M ago
PYC
PYC to unveil early clinical data on first-in-class gene-targeted eye drugs at ARVO
PremiumCompany Announcements
PYC to unveil early clinical data on first-in-class gene-targeted eye drugs at ARVO
3M ago
PYC
PYC Therapeutics Issues New Shares Following Option Exercise and Lodges Cleansing Notice
PremiumCompany Announcements
PYC Therapeutics Issues New Shares Following Option Exercise and Lodges Cleansing Notice
3M ago
PYC
PYC Therapeutics Lists Additional 250,000 Shares on ASX
PremiumCompany AnnouncementsPYC Therapeutics Lists Additional 250,000 Shares on ASX
3M ago
PYC
PYC Therapeutics Advances Genetic Disease Pipeline After $600m Capital Raise
Premium
Company Announcements
PYC Therapeutics Advances Genetic Disease Pipeline After $600m Capital Raise
3M ago
PYC
PYC Wins EMA Orphan Status for RP11 Gene Therapy Candidate VP-001
Premium
Company Announcements
PYC Wins EMA Orphan Status for RP11 Gene Therapy Candidate VP-001
3M ago
PYC
PYC Therapeutics Wins Safety Nod to Advance ADOA Drug PYC-001 to Multi-Dose Trial
PremiumCompany Announcements
PYC Therapeutics Wins Safety Nod to Advance ADOA Drug PYC-001 to Multi-Dose Trial
3M ago
PYC
PYC Therapeutics CEO Increases Shareholding and Receives Major Option Grant
PremiumCompany Announcements
PYC Therapeutics CEO Increases Shareholding and Receives Major Option Grant
4M ago
PYC
PYC Therapeutics to Showcase PKD Drug Progress at World Nephrology Congress
PremiumCompany Announcements
PYC Therapeutics to Showcase PKD Drug Progress at World Nephrology Congress
4M ago
PYC
PYC Therapeutics Advances ADOA Drug PYC-001 With New Clinical Data and Ongoing Trial
PremiumCompany Announcements
PYC Therapeutics Advances ADOA Drug PYC-001 With New Clinical Data and Ongoing Trial
4M ago
PYC
PYC Therapeutics: Strengthened Balance Sheet and Expanded Development Plan Underpin Continued Buy Rating
PremiumRatingsPYC Therapeutics: Strengthened Balance Sheet and Expanded Development Plan Underpin Continued Buy Rating
4M ago
PYC Therapeutics CEO Increases Shareholding and Awaits Approval for New Options Grant
Premium
Company Announcements
PYC Therapeutics CEO Increases Shareholding and Awaits Approval for New Options Grant
4M ago
PYC
PYC Therapeutics Seeks ASX Quotation for Over 10.5 Million New Shares
Premium
Company Announcements
PYC Therapeutics Seeks ASX Quotation for Over 10.5 Million New Shares
5M ago
PYC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >